Pharma BD Deal Intelligence
Focused rare disease merger built Sobi into a viable specialty biopharma
Full analysis, sources & comparables →Biovitrum AB acquired Swedish Orphan International Holding AB for approximately SEK 1.9 billion ($493M) in cash and shares, creating Swedish Orphan Biovitrum (Sobi), a leading European rare disease company focused on hemophilia, inflammation, and genetic diseases.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Swedish Orphan Biovitrum AB / Biovitrum (this deal) | 2001 | $493M | 84 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| Swedish Orphan Biovitrum AB / CTI BioPharma Corp. | 2023 | $1.7B | 60 |
| Swedish Orphan Biovitrum AB / Arthrosi Therapeutics, Inc. | 2025 | $1.5B | — |
| Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc. | 2020 | $1.0B | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
← Browse all deals · How we score deals
More: 2001 deals · Swedish Orphan Biovitrum AB deals · Hematology deals